# Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis

> **NCT07347626** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 786 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Eptifibatide (Integrilin)
- **DRUG:** Standard Medical Therapy

## Key facts

- **NCT ID:** NCT07347626
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2029-09-30
- **Final completion:** 2029-12-31
- **Target enrollment:** 786 (ESTIMATED)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07347626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07347626, "Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07347626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*